3737 (3737) Fair Value & Analysis

Healthcare · Market cap HK$574M

3 3737 3737 · HK

PriceHK$0.7000

Fair ValueHK$0.3500

Upside-50.0%

Quality53/100

Watch 3737 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.2600 – HK$0.4400

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −5.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.5200 – HK$0.9100 · fair‑value band HK$0.2600 – HK$0.4400 · the HK$0.7000 price screens above the HK$0.3500 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

3737 (3737) currently trades at HK$0.7000, while our model-based Fair Value estimate is HK$0.3500 — implying the stock looks roughly 50.0% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 3737 generated revenue of HK$1.7B at a net margin of 1.0%. Revenue declined 23.9% year over year. It earns a return on equity of 1.6%. Net debt stands at HK$26.1M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.7B

Revenue growth (YoY) -23.9%

Net margin 1.0%

Return on equity 1.6%

Free cash flow HK$69.9M FY2025

P/E ratio 34.0

More key figures

Operating margin 0.6%

EPS (TTM) HK$0.0100

EPS growth (YoY) -7.9%

Net debt HK$26.1M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3737 reported revenue of HK$1.7B in FY2025 versus HK$1.7B in FY2021, a compound −0.1%/yr. Reported net income was HK$17.3M in FY2025, compounding −24.1%/yr from FY2021.

Revenue −0.1%/yr

FY21 HK$1.7B

FY22 HK$1.8B

FY23 HK$2.0B

FY24 HK$2.2B

FY25 HK$1.7B

Net income −24.1%/yr

FY21 HK$52.1M

FY22 HK$106M

FY23 HK$163M

FY24 HK$95.2M

FY25 HK$17.3M

Is 3737 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.01	¥26.59	-43%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 3737 (3737) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.3500 versus a price of HK$0.7000 — about −50% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 3737?

Our model-based fair value for 3737 is HK$0.3500 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.7000.

What is the quality score of 3737?

3737 has a Quality Score of 53/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 3737 (3737)?

3737 reported trailing-twelve-month revenue of about HK$1.7B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 3737?

The net profit margin of 3737 is about 1.0%, meaning it keeps roughly 1.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.